CytoSorbents Corporation reported its financial results for the first quarter of 2025, highlighting a slight decrease in product sales. Q1 2025 product sales amounted to $8.7 million, representing a 3% year-over-year decrease. Despite this decline, on a constant currency basis, sales were flat. The company experienced strong performance from international distribution and other direct sales countries, which significantly offset the disruption in German direct sales. This disruption was due to a proactive reorganization and strategic realignment of the German sales team and strategy during the quarter. The company aims to return to growth in Germany in the second half of 2025, following two consecutive years of flat sales. The product gross margin remained steady at 71%, consistent with the average from 2024. CytoSorbents is also making significant operational progress, with a focus on managing its total core business towards near breakeven in the second half of 2025. The company continues to leverage its platform blood purification technology, with two main products designed for the treatment of life-threatening conditions in the ICU and cardiac surgery. In 2024, CytoSorbents recorded core product sales of $35.6 million. CytoSorbents remains committed to addressing operational challenges and executing strategic initiatives to drive future growth and profitability.